Cambridge Isotope Laboratories (CIL), a subsidiary of Japan’s Otsuka Pharmaceutical, has signed a Memorandum of Understanding (MoU) with Hyderabad-based Chemtatva Chiral Solutions (CCS) to establish a new entity — Cambridge Isotope Laboratories Pvt. Ltd. — in Hyderabad, India.

The partnership marks a significant step in expanding CIL’s global footprint and strengthening its capabilities in developing and producing deuterated reagents and other isotopically enriched products. It is also expected to enhance global supply chain strength and real-time support for customers in Asia.

The new entity is set to be formally established in the fourth quarter of 2025, pending customary diligence and closing procedures. Initial operations will commence at CCS’s existing facilities, with plans to build a new facility in Hyderabad’s Genome Valley in 2026.

Cliff Caldwell, CEO at CIL, commented, "We are excited to partner with CCS to combine our chemistry expertise and pursue scale-up technologies to further support pharmaceutical and industrial applications. This initiative reflects our commitment to supporting global research and development efforts in scientific fields, as well as supporting the growing commercial needs for deuterium-labeled and specialty chemical products in the pharmaceutical and electronics industries."

Vishal Rajput, CEO of CCS, said, "The collaboration and newly formed entity will leverage CCS's strong infrastructure and deep technical capabilities in India, while integrating CIL's world-class standards in isotope chemistry, quality systems, global logistics and go-to market capabilities."  

Rajput will lead the new entity as General Manager of Cambridge Isotope Laboratories Pvt. Ltd. The existing CCS business will continue to operate independently, with a shared goal of expanding global access to high-quality isotopically labeled and unlabeled compounds for pharmaceutical and industrial customers.

All CIL, Eurisotop and CCS-branded materials will remain available to customers in India and worldwide through existing channels.

CIL is a global leading manufacturer and supplier of stable isotopes and labeled compounds, while CCS specialises in chiral chemistry, process development and custom synthesis for the pharmaceutical and chemical sectors.